UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1351-5
Program Prior Authorization/Notification
Medication Orladeyo® (berotralstat)
P&T Approval Date 3/2021, 3/2022, 3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Orladeyo is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary
angioedema (HAE) in adults and pediatric patients 12 years and older. Orladeyo should not be used
for the treatment of acute HAE attacks.1
2. Coverage Criteriaa:
A. Orladeyo will be approved based on all of the following criteria:
1. Diagnosis of hereditary angioedema (HAE)
-AND-
2. Both of the following:
a. For prophylaxis against HAE attacks
-AND-
b. Not used in combination with other products indicated for prophylaxis against HAE
attacks (e.g., Cinryze, Haegarda, Takhzyro)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Orladeyo [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc.; October 2024.
© 2025 UnitedHealthcare Services Inc.
1
Program Prior Authorization/Notification – Orladeyo (berotralstat)
Change Control
3/2021 New program.
3/2022 Annual review. Aligned combination use language with prophylactic
therapies without change to clinical intent.
3/2023 Annual review. Added state mandate and updated reference.
3/2024 Annual review with no changes to clinical criteria.
3/2025 Annual review with no changes to clinical criteria.
© 2025 UnitedHealthcare Services Inc.
2